Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METCHNIKOFF: Evolocumab in Diabetes and ASCVD
NCT03829046Phase 4Completed
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in atherosclerotic vascular disease (ASVD) comparing Placebo with Evolocumab (2 arms). Primary endpoint: Number of Adverse Events at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic vascular disease (ASVD)
Beyond the preview
Go deeper on NCT03829046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829046.